20. Clinical characteristics and survival outcome of patients diagnosed with ALK gene mutated non-small lung cancer treated with the second generation tkis - ceritinib at K Hospital and Hanoi Oncology Hospital in Vietnam
Main Article Content
Abstract
This is a retrospective and prospective descriptive study to evaluate characteristics and survival outcomes in 69 NSCLC patients with ALK gene mutations from January 2019 to June 2022 at K Hospital and Hanoi Oncology Hospital. The results show that the average age is 52.6 ± 11.5 years common in female representing 52.2%; the majority of patients were non-smokers. Brain metastasis had a high rate of 36.2%. Adenocarcinoma is the main type with 89.9%. NGS test identified mutations in ALK gene accounted for 55.1%; RT-PCR accounted for 27.5%, immunohistopathology staining 13.0% and FISH 4.3%. 97.1% were performed on tissue samples. The mean progression-free survival was 19.5 ± 2.1 months. The mean overall survival was 23.5 ± 2.2 months.
Article Details
Keywords
second-generation tyrosine kinase, ALK gen mutation, ceritinib, lung cancer
References
2. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A cancer journal for clinicians. 2021;71(3):209-249.
3. Nguyễn Hoài Nga BD, Trần Văn Thuấn, và cs. Một số đặc điểm dịch tễ, lâm sàng, cận lâm sàng ung thư phổi nguyên phát chẩn đoán điều trị tại bệnh viện K trong 10 năm từ 2001 đến 2010. Tạp chí Ung thư học Việt Nam. 2014;số 2:7.
4. Network NCC. NCCN clinical practice guidelines in oncology (NCCN Guidelines™): Non-small-cell lung cancer. Version 7.2019. www.nccn.org, 10/29/2019.
5. Pan-Chyr Yang YS, Joseph Siu-kie Au, et al. Molecular Epidemiological prospective study of EGFR mutation from Asian patients with advanced lung adenocarcinoma (PIONEER). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30:1534.
6. Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014;9(2):154-162.
7. Lipson D CM, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18:382-384.
8. Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet (London, England). 2017;389(10072):917-929.
9. Gobbini E, Galetta D, Tiseo M, et al. Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study. Lung cancer (Amsterdam, Netherlands). 2017;111:30-37.
10. Jahanzeb M, Lin HM, Pan X, et al. Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer. The oncologist. 2020;25(10):867-877.
11. Kiura K, Imamura F, Kagamu H, et al. Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset. Japanese journal of clinical oncology. 2018;48(4):367-375.
12. Hida T, Satouchi M, Nakagawa K, et al. Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset. Japanese journal of clinical oncology. 2017;47(7):618-624.